Efatutazone, an Oral PPAR-γ Agonist, in Combination With Paclitaxel in Anaplastic Thyroid Cancer: Results of a Multicenter Phase 1 Trial
Smallridge, R. C, Copland, J. A, Brose, M. S, Wadsworth, J. T, Houvras, Y, Menefee, M. E, Bible, K. C, Shah, M. H, Gramza, A. W, Klopper, J. P, Marlow, L. A, Heckman, M. G, Von Roemeling, R
Published in The journal of clinical endocrinology and metabolism (01.06.2013)
Published in The journal of clinical endocrinology and metabolism (01.06.2013)
Get full text
Journal Article
Targeted Inhibition of CD133+ Cells in Oral Cancer Cell Lines
Damek-Poprawa, M., Volgina, A., Korostoff, J., Sollecito, T.P., Brose, M.S., O’Malley, B.W., Akintoye, S.O., DiRienzo, J.M.
Published in Journal of dental research (01.05.2011)
Published in Journal of dental research (01.05.2011)
Get full text
Journal Article
Absence of BRAF mutations in UV-protected mucosal melanomas
Edwards, R H, Ward, M R, Wu, H, Medina, C A, Brose, M S, Volpe, P, Nussen-Lee, S, Haupt, H M, Martin, A M, Herlyn, M, Lessin, S R, Weber, B L
Published in Journal of medical genetics (01.04.2004)
Published in Journal of medical genetics (01.04.2004)
Get full text
Journal Article
The RET/PTC3 oncogene activates classical NF-κB by stabilizing NIK
NEELY, R. J, BROSE, M. S, GRAY, C. M, MCCORKELL, K. A, LEIBOWITZ, J. M, MA, C, ROTHSTEIN, J. L, MAY, M. J
Published in Oncogene (06.01.2011)
Published in Oncogene (06.01.2011)
Get full text
Journal Article
Larotrectinib in adult patients with solid tumours: a multi-centre, open-label, phase I dose-escalation study
Hong, D.S., Bauer, T.M., Lee, J.J., Dowlati, A., Brose, M.S., Farago, A.F., Taylor, M., Shaw, A.T., Montez, S., Meric-Bernstam, F., Smith, S., Tuch, B.B., Ebata, K., Cruickshank, S., Cox, M.C., Burris, H.A., Doebele, R.C.
Published in Annals of oncology (01.02.2019)
Published in Annals of oncology (01.02.2019)
Get full text
Journal Article
Preliminary results from a phase II trial of tipifarnib in squamous cell carcinomas (SCCs) with HRAS mutations
Ho, A.L., Chau, N., Bauman, J., Bible, K., Chintakuntlawar, A., Cabanillas, M.E., Wong, D.J., Braña Garcia, I., Brose, M.S., Boni, V., Even, C., Razaq, M., Mishra, V., Bracken, K., Wages, D., Scholz, C., Gualberto, A.
Published in Annals of oncology (01.10.2018)
Published in Annals of oncology (01.10.2018)
Get full text
Journal Article
Cancer Risk Estimates for BRCA1 Mutation Carriers Identified in a Risk Evaluation Program
Brose, Marcia S., Rebbeck, Timothy R., Calzone, Kathleen A., Stopfer, Jill E., Nathanson, Katherine L., Weber, Barbara L.
Published in JNCI : Journal of the National Cancer Institute (18.09.2002)
Published in JNCI : Journal of the National Cancer Institute (18.09.2002)
Get full text
Journal Article
The RET/PTC3 oncogene activates classical NF-[kappa]B by stabilizing NIK
Neely, R J, Brose, M S, Gray, C M, Mccorkell, K A, Leibowitz, J M, Ma, C, Rothstein, J L, May, M J
Published in Oncogene (06.01.2011)
Published in Oncogene (06.01.2011)
Get full text
Journal Article
Germline CHEK21100delC mutations in breast cancer patients with multiple primary cancers
Huang, J, Domchek, S M, Brose, M S, Rebbeck, T R, Nathanson, K L, Weber, B L
Published in Journal of medical genetics (01.11.2004)
Published in Journal of medical genetics (01.11.2004)
Get full text
Journal Article
A randomized study to evaluate the safety and efficacy of two dosages of lenvatinib – 18 and 24 mg – in patients with radioiodrefract differentiated thyroid cancer
Brose, M. S., Panaseykin, Yu, Konda, B., De la Fouchardiere, C., Hughes, B. G.M., Gianoukakis, A. G., Park, Y. J., Romanov, I., Krzyzanowska, M. K., Leboulleux, S., Binder, T. A., Dutcus, C., Xie, R., Taylor, M. H.
Published in Opukholi golovy i shei (11.04.2022)
Published in Opukholi golovy i shei (11.04.2022)
Get full text
Journal Article
Влияние прерывания терапии ленватинибом на общую эффективность лечения у пациентов с радиойодрезистентным дифференцированным раком щитовидной железы в исследовании III фазы
Tahara, M., Brose, M. S., Wirth, L. J., Suzuki, T., Miyagishi, H., Fujino, K., Dutcus, C. E., Gianoukakis, A.
Published in Opukholi golovy i shei (03.04.2019)
Published in Opukholi golovy i shei (03.04.2019)
Get full text
Journal Article
Лечение токсических побочных эффектов у пациентов с распространенным медуллярным раком щитовидной железы
Brose, M. S., Bible, K. C., Chow, L. Q. M., Gilbert, J., Grande, C., Worden, F., Haddad, R.
Published in Opukholi golovy i shei (03.04.2019)
Published in Opukholi golovy i shei (03.04.2019)
Get full text
Journal Article
Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children
Drilon, Alexander, Laetsch, Theodore W, Kummar, Shivaani, DuBois, Steven G, Lassen, Ulrik N, Demetri, George D, Nathenson, Michael, Doebele, Robert C, Farago, Anna F, Pappo, Alberto S, Turpin, Brian, Dowlati, Afshin, Brose, Marcia S, Mascarenhas, Leo, Federman, Noah, Berlin, Jordan, El-Deiry, Wafik S, Baik, Christina, Deeken, John, Boni, Valentina, Nagasubramanian, Ramamoorthy, Taylor, Matthew, Rudzinski, Erin R, Meric-Bernstam, Funda, Sohal, Davendra P.S, Ma, Patrick C, Raez, Luis E, Hechtman, Jaclyn F, Benayed, Ryma, Ladanyi, Marc, Tuch, Brian B, Ebata, Kevin, Cruickshank, Scott, Ku, Nora C, Cox, Michael C, Hawkins, Douglas S, Hong, David S, Hyman, David M
Published in The New England journal of medicine (22.02.2018)
Published in The New England journal of medicine (22.02.2018)
Get full text
Journal Article
Phase 3 Trial of Selpercatinib in Advanced RET-Mutant Medullary Thyroid Cancer
Hadoux, Julien, Elisei, Rossella, Brose, Marcia S., Hoff, Ana O., Robinson, Bruce G., Gao, Ming, Jarzab, Barbara, Isaev, Pavel, Kopeckova, Katerina, Wadsley, Jonathan, Führer, Dagmar, Keam, Bhumsuk, Bardet, Stéphane, Sherman, Eric J., Tahara, Makoto, Hu, Mimi I., Singh, Ravinder, Lin, Yan, Soldatenkova, Victoria, Wright, Jennifer, Lin, Boris, Maeda, Patricia, Capdevila, Jaume, Wirth, Lori J.
Published in The New England journal of medicine (16.11.2023)
Published in The New England journal of medicine (16.11.2023)
Get full text
Journal Article
1046OPreliminary results from a phase II trial of tipifarnib in squamous cell carcinomas (SCCs) with HRAS mutations
Ho, A L, Chau, N, Bauman, J, Bible, K, Chintakuntlawar, A, Cabanillas, M E, Wong, D J, Braña Garcia, I, Brose, M S, Boni, V, Even, C, Razaq, M, Mishra, V, Bracken, K, Wages, D, Scholz, C, Gualberto, A
Published in Annals of oncology (01.10.2018)
Published in Annals of oncology (01.10.2018)
Get full text
Journal Article
994OLenvatinib (LEN) and pembrolizumab (PEMBRO) in advanced endometrial cancer (EC)
Makker, V, Taylor, M H, Aghajanian, C, Oaknin, A, Mier, J, Cohn, A L, Marin, M Romeo, Lorenzo, R Bratos, Brose, M S, DiSimone, C, Messing, M J, Stepan, D E, Dutcus, C E, Wu, J, Schmidt, E V, Orlowski, R J, Sachdev, P, Shumaker, R, Herraez, A Casado
Published in Annals of oncology (01.10.2019)
Published in Annals of oncology (01.10.2019)
Get full text
Journal Article
Characterization of two novel BRCA1 germ-line mutations involving splice donor sites
Brose, M S, Volpe, P, Paul, K, Stopfer, J E, Colligon, T A, Calzone, K A, Weber, B L
Published in Genetic testing (01.06.2004)
Published in Genetic testing (01.06.2004)
Get more information
Journal Article